Antibody-Drug Conjugates: The Dynamic Evolution from Conventional to Next-Generation Constructs

Area of Science:

• Oncology
• Pharmacology
• Biotechnology

Background:

• Antibody-drug conjugates (ADCs) represent a significant advancement in targeted cancer therapy, offering clinical benefits to patients.
• Despite initial development challenges due to their complexity, recent progress has accelerated ADC approvals and late-stage clinical development.

Purpose of the Study:

• To review recent trends in the antibody-drug conjugate field.
• To focus on construct design, mechanism of action, and their impact on therapeutic profiles.
• To illustrate the evolution of ADCs from conventional to innovative formats and discuss future directions.

Main Methods:

• Literature review of recent trends in ADC development.
• Analysis of construct design, conjugation technologies, and linker strategies.
• Examination of mechanisms of action and their influence on therapeutic outcomes.

Main Results:

• Significant increase in approved ADCs and those in late-stage development.
• Diversification of targets, payloads, conjugation methods, and linker technologies driving next-generation ADCs.
• Identification of key hurdles including toxicity and drug resistance.

Conclusions:

• Next-generation ADCs, with diversified targets and payloads, offer renewed hope for treating difficult-to-treat cancers.
• Continued innovation in ADC design and delivery is crucial for overcoming current limitations.
• Future research should focus on improving ADC design to enhance efficacy and mitigate resistance and toxicity.